LAV694, a new antiproliferative agent showing improved skin tolerability vs. clinical standards for the treatment of actinic keratosis

Biochemical Pharmacology

Volumn 66, Issue 10, 2003, Pages 1885-1895

  Medina, Jesús ^a   Picarles, Valérie ^a   Greiner, Brigitte ^a   Elsaesser, Christian ^a   Kolopp, Maryelle ^a   Mahl, Andreas ^a   Roman, Danielle ^a   Vogel, Beate ^a   Nussbaumer, Peter ^b   Winiski, Anthony ^b   Meingassner, Josef ^b   De Fraissinette, Anne De Brugerolle ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Novartis Research Institute   (Austria)

Author keywords

Actinic keratosis; Apoptosis; Human reconstructed epidermis; Irritation; Minipig; Pro inflammatory cytokines

Indexed keywords

ANTIMITOTIC AGENT; FLUOROURACIL; INTERLEUKIN 8; LACTATE DEHYDROGENASE; LAV 694; MESSENGER RNA; PLACEBO; PODOPHYLLOTOXIN; TUBULIN POLYMERIZATION INHIBITOR; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BASEMENT MEMBRANE; CELL CYCLE; CELL CYCLE PHASE; CELL ULTRASTRUCTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOMETRY; DERMOEPIDERMAL JUNCTION; DISEASE SEVERITY; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; KERATINOCYTE; LASER MICROSCOPY; MALE; MICROTUBULE ASSEMBLY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKIN MANIFESTATION; TOXICITY TESTING; VISUAL ANALOG SCALE;

EID: 0242298296     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00369-1     Document Type: Article

References (49)

1. Salasche S.J. Epidemiology of actinic keratoses and squamous cell carcinoma. J. Am. Acad. Dermatol. 42:2000;4-7.
2. Cockerell C.J. Histopathology of incipient intraepidermal squamous cell carcinoma. J. Am. Acad. Dermatol. 42:2000;11-17.
3. Dinehart S.M. The treatment of actinic keratoses. J. Am. Acad. Dermatol. 42:2000;25-28.
4. Nussbaumer P., Winiski A., Cammisuli S., Hiestand P., Weckbecker G., Stuetz A. Novel antiproliferative agents derived from lavendustin A. J. Med. Chem. 37:1994;4079-4084.
5. Cammisuli S., Winiski A., Nussbaumer P., Hiestand P., Stutz A., Weckbecker G. SDZ 281-977: a modified partial structure of lavendustin A that exerts potent and selective antiproliferative activities in vitro and in vivo. Int. J. Cancer. 65:1996;351-359.
6. Ure I., Niederecker C., Nussbaumer P. SDZ LAP 977, a potent and selective anti-proliferative agent indicates therapeutic efficacy in AK. Skin Pharmacol. 9:1996;166-167.
7. Nussbaumer P., Billich A., Meingassner J.G., Winiski A.P. SDZ LAV 694: a novel antiproliferative agent for topical use (Abstract). Drug Future. 27(Suppl. A):2002;61.
8. Rosdy M., Clauss L.C. Terminal epidermal differentiation of human keratinocytes grown in chemically defined medium on inert filter substrates at the air-liquid interface. J. Invest. Dermatol. 95:1990;409-414.
9. ®) applied to the testing of topical vehicles. Cell Biol. Toxicol. 15:1999;121-135.
10. Danpure C.J. Lactate dehydrogenase and cell injury. Cell. Biochem. Funct. 2:1984;144-148.
11. Barker J.N., Jones M.L., Mitra R.S., Crockett-Torabe E., Fantone J.C., Kunkel S.L., Warren J.S., Dixit V.M., Nickoloff B.J. Modulation of keratinocyte-derived interleukin-8, which is chemotactic for neutrophils and T-lymphocytes. Am. J. Pathol. 139:1991;869-876.
12. Boelsma E., Tanojo H., Boddé H.E., Ponec M. Assessment of the potential irritancy of oleic acid on human skin: evaluation in vitro and in vivo. Toxicol. In Vitro. 10:1996;729-742.
13. Boelsma E., Tanojo H., Boddé H.E., Ponec M. An in vivo-in vitro study of the use of a human skin equivalent for irritancy screening of fatty acids. Toxicol. In Vitro. 11:1997;365-376.
14. Griffiths C.E.M., Barker J.N.W.N., Kunkel S., Nickoloff B.J. Modulation of leucocyte adhesion molecule, a T cell chemotaxin (IL-8) and a regulatory cytokine (TNF-α) in allergic contact dermatitis (rhus dermatitis). Br. J. Dermatol. 124:1991;519-526.
15. Mohamadzadeh M., Muller M., Hultsch T., Enk A., Saloga J., Knop J. Enhanced expression of IL-8 in normal human keratinocytes and human keratinocyte cell line HaCaT in vitro after stimulation with contact sensitizers, tolerogens and irritants. Exp. Dermatol. 3:1994;298-303.
16. Schröder J.M. Cytokine networks in the skin. J. Invest. Dermatol. 105:1995;20S-24S.
17. Green D.R., Reed J.C. Mitochondria and apoptosis. Science. 281:1998;1309-1312.
18. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 281:1998;1322-1326.
19. Evan G., Littlewood T. A matter of life and cell death. Science. 281:1998;1317-1322.
20. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science. 281:1998;1312-1316.
21. Svendsen O. The minipig in toxicology. Scand. J. Lab. Anim. Sci. 25:1998;1-15.
22. Xing Q.F., Lin S., Chien Y.W. Transdermal testosterone delivery in castrated Yucatan minipigs: pharmacokinetics and metabolism. J. Control Release. 52:1998;89-98.
23. Kamentsky L.A., Burger D.E., Gershman R.J., Kamentsky L.D., Luther E. Slide-based laser scanning cytometry. Acta Cytologica. 41:1997;123-143.
24. Savill J. Recognition and phagocytosis of cells undergoing apoptosis. Br. Med. Bull. 53:1997;491-508.
25. Voll R.E., Herrmann M., Roth E.A., Stach C., Kalden J.R. Immunosuppressive effects of apoptotic cells. Nature. 390:1997;350-351.
26. Fadok V.A., Bratton D.L., Konowal A., Freed P.W., Westcott J.Y., Henson P.M. Macrophages that have ingested apoptosis cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J. Clin. Invest. 101:1998;890-898.
27. Gao Y., Herndon J.M., Zhang H., Griffith T.S., Ferguson T.A. Anti-inflammatory effects of CD95 ligand (FasL)-induced apoptosis. J. Exp. Med. 188:1998;887-896.
28. Ronchetti A., Rovere P., Iezzi G., Galati G., Heltai S., Protti M.P., Garancini M.P., Manfredi A.A., Rugarli C., Bellone M. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J. Immunol. 163:1999;130-136.
29. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188:1998;1359-1368.
30. Hale A.J., Smith C.A., Sutherland L.C., Stoneman V.E., Longthorne V.L., Culhane A.C., Williams G.T. Apoptosis: molecular regulation of cell. Eur. J. Biochem. 236:1996;1-26.
31. Antonsson B., Conti F., Ciavatta A., Montessuit S., Lewis S., Martinou I., Bernasconi L., Bernard A., Mermod J.J., Mazzei G., Maundrell K., Gambale F., Sadoul R., Martinou J.C. Inhibition of Bax channel-forming activity by Bcl-2. Science. 277:1997;370-372.
32. Lazebnik Y.A., Cole S., Cooke C.A., Nelson W.G., Earnshaw W.C. Nuclear events of apoptosis in vitro in cell-free mitotic extracts: a model system for analysis of the active phase of apoptosis. J. Cell Biol. 123:1993;7-22.
33. Liu X., Kim C.N., Yang J., Jemmerson R., Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 86:1996;147-157.
34. Patel T., Gores G.J., Kaufmann S.H. The role of proteases during apoptosis. FASEB J. 10:1996;587-597.
35. Stennicke H.R., Salvesen G.S. Caspases - controlling intracellular signals by protease zymogen activation. Biochim. Biophys. Acta. 1477:2000;299-306.
36. Cohen G.M. Caspases: the executioners of apoptosis. Biochem. J. 326:1997;1-16.
37. Amundson S.A., Myers T.G., Fornace A.J. Jr. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene. 17:1998;3287-3299.
38. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
39. Owen-Schaub L.B., Zhang W., Cusack J.C., Angelo L., Santee S.M., Fujiwara T., Roth A., Deisseroth A., Zhang W., Kruzel E., Radinsky R. Wild-type human p53 and a temperature - sensitive mutant induce Fas/APO-1 expression. Mol. Cell Biol. 15:1995;3032-3040.
40. Muller M., Wilder S., Bannasch D., Israeli D., Lehlbach K., Li-Weber M., Friedman S.L., Galle P.R., Stremmel W., Oren M., Krammer P.H. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188:1998;2033-2045.
41. Wu G.S., Burns T.F., McDonald E.R. Jr., Jiang W., Meng R., Krantz I.D., Kao G., Gan D.D., Zhou J.Y., Muschel R., Hamilton S.R., Spinner N.B., Markowitz S., Wu G., el-Deiry W.S. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17:1997;141-143.
42. Yin Y., Terauchi Y., Solomon G.G.et al. Involvement of p85 in p53-dependent apoptotic response to oxidative stress. Nature. 391:1998;707-710.
43. Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B., Seizinger B.R., Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature. 377:1995;646-649.
44. Saller E., Tom E., Brunori M., Otter M., Estreicher A., Mack D.H., Iggo R. Increased apoptosis induction by 121F mutant p53. EMBO J. 18:1999;4424-4437.
45. Polyak K., Xia Y., Zweier J.L., Kinzler K.W., Vogelstein B. A model for p53-induced apoptosis. Nature. 389:1997;300-305.
46. Berthou C., Michel L., Soulie A., Jean-Louis F., Flageul B., Dubertret L., Sigaux F., Zhang Y., Sasportes M. Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defense. J. Immunol. 159:1997;5293-5300.
47. Smyth M.J., Trapani J.A. Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol. Today. 16:1995;202-206.
48. Shi L., Kraut R.P., Aebersold R., Greenberg A.H. A natural killer cell granule protein that induces DNA fragmentation and apoptosis. J. Exp. Med. 175:1992;553-566.
49. Trapani J.A., Browne K.A., Smyth M.J., Jans D.A. Localization of granzyme B in the nucleus. A putative role in the mechanism of cytotoxic lymphocyte-mediated apoptosis. J. Biol. Chem. 271:1996;4127-4133.